Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC(R), a cell-free hydrogel implant designed to repair knee cartilage damage through a single approximately 10-minute procedure, positioning the company to address a major unmet need in orthopedic medicine. While roughly 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, no approved off-the-shelf regenerative solution capable of restoring hyaline-like cartilage currently exists in the U.S. market. Unlike traditional microfracture procedures or complex cell-based therapies that often require multiple surgeries and lengthy preparation, GelrinC(R) is designed as a ready-to-use implant that supports native cartilage regeneration over time. The product has already received CE Mark approval in Europe and is advancing through a pivotal U.S. FDA trial that is now more than 50% enrolled. Regentis is also preparing for potential commercialization, highlighted by a newly patented solvent-free manufacturing process that increased production yield by 400%, alongside ongoing efforts to build physician adoption infrastructure across Europe.
To view the full article, visit https://ibn.fm/TrCv1
About Regentis Biomaterials
Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
